Kura Oncology, Inc.

NASDAQ:KURA

8.98 (USD) • At close December 26, 2024
Bedrijfsnaam Kura Oncology, Inc.
Symbool KURA
Munteenheid USD
Prijs 8.98
Beurswaarde 698,318,026
Dividendpercentage 0%
52-weken bereik 8.75 - 24.17
Industrie Biotechnology
Sector Healthcare
CEO Dr. Troy Edward Wilson J.D., Ph.D.
Website https://kuraoncology.com

An error occurred while fetching data.

Over Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the

Vergelijkbare Aandelen

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.579 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

2.915 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

6 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.319 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

1.7 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

42.03 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

12.28 USD

Phibro Animal Health Corporation logo

Phibro Animal Health Corporation

PAHC

21.68 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

12.925 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

16.81 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)